0011M Medicare Reimbursement Rate (2026)
Current CMS pricing and breakdown for Onc prst8 ca mrna 12 gen alg.
National Average Payment
National Medicare Payment
$760.00
This fee schedule does not publish separate facility and non-facility rates for this code.
Effective Q4 2026
ℹ️ Good to Know
This item has a standard price nationwide. Your local rate will likely match the amount shown above.
Historical Medicare Reimbursement
| Quarter | National Medicare Payment | YoY % Change |
|---|---|---|
| 2026 Q4 | $760.00 | +0.00% |
| 2026 Q3 | $760.00 | +0.00% |
| 2026 Q2 | $760.00 | +0.00% |
| 2026 Q1 | $760.00 | +0.00% |
| 2025 Q4 | $760.00 | — |
| 2025 Q3 | $760.00 | — |
| 2025 Q2 | $760.00 | — |
| 2025 Q1 | $760.00 | — |
Code Description
Oncology, prostate cancer, mrna expression assay of 12 genes (10 content and 2 housekeeping), rt-pcr test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk
Reimbursement Summary
CPT code 0011M (Oncology, prostate cancer, mrna expression assay of 12 genes (10 content and 2 housekeeping), rt-pcr test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk) had a 2026 Medicare non-facility reimbursement rate of $760.00. This reflects a 0.00% change from the prior year.
The 2026 National Medicare reimbursement for 0011M is $760.00. This item is paid at a standard national rate, so local variation is typically minimal.
Description: Oncology, prostate cancer, mrna expression assay of 12 genes (10 content and 2 housekeeping), rt-pcr test utilizing blood plasma and urine, algorithms to predic.... Payment policies and coverage rules can still vary by setting and claim details, so confirm final guidance through CMS when needed.
Q4 2026 Breakdown
| Component | Office (Non-Fac) | Facility (Hosp) |
|---|---|---|
| Work RVU | ||
| Practice Expense (PE) | ||
| Malpractice (MP) | ||
| Total RVUs | 0.00 | 0.00 |
Are you being paid correctly for this code?
Compare a payment against the Medicare benchmark for this code.
Medicare rates are used as a benchmark only. Actual payer contracts, modifiers, place of service, units, and billing rules may affect reimbursement. This tool is for educational and operational review purposes, not legal or billing advice.
Facility vs. Non-Facility (Office) Payment
Facility vs. non-facility pricing most commonly applies to physician services paid under the RVU-based Physician Fee Schedule. For 0011M (Clinical Laboratory Test), the payment methodology may not include both facility and non-facility rates.
Learn How This Reimbursement Is Calculated
Medicare reimbursement is determined by RVUs, geographic adjustments, and the annual conversion factor.
Frequently Asked Questions
What is the 2026 Medicare rate for 0011M?
The 2026 National Average Medicare reimbursement rate for 0011M (Clinical Laboratory Test) is $760.00. This rate is effective as of January 1, 2026.
What is the description for code 0011M?
Oncology, prostate cancer, mrna expression assay of 12 genes (10 content and 2 housekeeping), rt-pcr test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk
Why do facility and non-facility payments differ for 0011M?
Facility vs. non-facility differences usually apply to RVU-based physician services. 0011M may not use both facility and non-facility pricing depending on its payment methodology.
How can I find my local Medicare rate for 0011M?
Use MedFeeSchedule's Medicare Physician Fee Schedule Lookup Tool on the homepage to estimate your locality-adjusted reimbursement. Medicare payment can vary based on geographic adjustments (GPCI), place of service, and claim specifics.
Is 0011M covered by Medicare?
Coverage depends on medical necessity, setting, and Medicare policy. Some codes may be bundled, contractor-priced, or restricted. Verify final coverage guidance through CMS or your local MAC when applicable.
